FDA approves new indication for YAZ(r) to treat the emotional and physical
symptoms of premenstrual dysphoric disorder (PMDD)

Berlin, October 5, 2006 - Schering AG, Germany (FSE: SCH, NYSE: SHR)
announced today that the U.S. Food and Drug Administration (FDA) has
approved YAZ (3 mg drospirenone/20 mcg ethinyl estradiol, in a 24-day
active pill regimen) as the first and only oral contraceptive that is also
clinically effective in treating the emotional and physical symptoms of
premenstrual dysphoric disorder (PMDD), for women who choose to use an oral
contraceptive as their method of contraception.

PMDD is a condition in which women's emotional and physical premenstrual
symptoms are disruptive enough to significantly impact relationships,
social activities and work productivity. Symptoms of PMDD include mood
swings, irritability, headaches, feeling anxious, bloating and food
cravings. The symptoms regularly occur seven to 10 days before menstruation
begins, and resolve within a few days of the onset of menses. While the
symptoms of PMDD and premenstrual syndrome (PMS) are the same, women with
PMDD experience five or more symptoms which are more severe. PMDD is also
linked to higher healthcare costs related to more frequent visits to
healthcare providers, decreased work productivity and absenteeism.

"We are absolutely delighted with this approval as YAZ will strengthen our
worldwide leading market position in the field of female contraception,"
said Philip Smits, M.D., Head of Gynecology&Andrology at Schering AG.
"Women have repeatedly told us they wanted relief from menstrual symptoms
in addition to reliable, safe birth control. Because our progestin,
drospirenone, has unique properties, we believed it had the potential to
offer this relief. This potential was realised in clinical studies that
showed YAZ was significantly superior to placebo across all symptoms of
PMDD."

YAZ is the first oral contraceptive to combine the unique progestin
drospirenone with 20 mcg of ethinyl estradiol in a 24-day active hormone
pill regimen. YAZ, which has been available in the U.S. since April 2006 as
an oral contraceptive, is the fastest growing oral contraceptive brand in
the U.S.

Additional Information

In a multicenter, double-blind, randomized, parallel clinical trial of 450
women aged 18-40 with symptoms of PMDD, YAZ was significantly superior to
placebo in improving interpersonal relationships, work productivity and
enjoyment of hobbies/social activities. Forty-eight percent of YAZ patients
experienced a reduction in symptom severity by at least half, as measured
by the Daily Record of Severity of Problems, a validated tool used to
diagnose PMDD by tracking premenstrual symptoms and their severity on a
daily basis.

In a separate multicenter, placebo-controlled, randomized, crossover,
confirmatory trial, patients experienced twice the improvement in symptoms
scores versus placebo.

The onset of PMDD symptoms occurs seven to 10 days before menstruation
starts (luteal phase) and the symptoms disappear within a few days after
the bleeding begins (follicular phase). A woman with PMDD suffers from
symptoms for about 2,800 days (totaling approximately eight years) out of
her life. PMDD affects as many as 4.5 million women in the United States
and nearly 90 percent of these women remain undiagnosed and untreated.1
According to standard diagnostic criteria, five or more premenstrual
symptoms must be present and severe enough to significantly interfere with
a woman's life. At least one of the symptoms must be an emotional symptom
such as mood swings, anger or irritability or tension. Physical symptoms
include breast tenderness, bloating and headache. Women with PMDD feel less
interest in daily activities, have difficulty concentrating and have food
cravings.2

References:

1 Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence,
  impairment, impact, and burden of premenstrual dysphoric disorder
  PMS/PMDD). Psychoneuroendocrinology 2003;28:1-23.
2 Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition,
  Text Revision. Washington, DC, American Psychiatric Association, 2000.

Schering AG is a research-based pharmaceutical company. Its activities are
focused on four business areas: Gynecology&Andrology, Oncology, Diagnostic
Imaging as well as Specialized Therapeutics for disabling diseases. As a
global player with innovative products, Schering AG aims for leading
positions in specialized markets worldwide. With in-house R&D and supported
by an excellent global network of external partners, Schering AG is
securing a promising product pipeline. Using new ideas, Schering AG aims to
make a recognized contribution to medical progress and strives to improve
the quality of life: making medicine work

It is planned that Schering AG will be renamed Bayer Schering Pharma
Aktiengesellschaft. A corresponding resolution was passed at the
Extraordinary General Meeting of Schering AG on September 13, 2006. Until
the name change has been registered in the commercial register, the company
will continue to operate under the name Schering AG. According to the
resolution of the General Meeting, the Executive Board will not file an
application for registration before December 1, 2006.

This press release has been published by Corporate Communication of
Schering AG, Berlin, Germany.

Your contacts at Corporate Communication:
Media Relations: Oliver Renner, T: +49-30-468 124 31,
oliver.renner@schering.de
Media Relations: Verena von Bassewitz, T: +49-30 468 192206,
verena.vonbassewitz@schering.de
Pharma Communication: Dr Claudia Schmitt, T: +49-30-468 158 05,
claudia.schmitt@schering.de
Investor Relations: Peter Vogt, T: +49-30-468 128 38,
peter.vogt@schering.de

Your contacts in the U.S.:
Media Relations: Rose Talarico, T: +1-973-305 5302,
rose_talarico@berlex.com
Investor Relations: Joanne Marion, T: +1-973-487 2164,
joanne_marion@berlex.com

Find additional information at: www.schering.de/eng